Vor Biopharma Inc. (VOR): Total Liabilities
$628.44M
As of 2025-12-31
$681.25M
As of 2026-06-30
+134.5%
3-year compound annual growth
+86.8%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $628.44M | n/m | 2026-03-30, Balance as of period end |
| 2024-12-31 | $46.23M | -2.5% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $47.40M | -2.8% | 2025-03-20, Balance as of period end |
| 2022-12-31 | $48.76M | +85.2% | 2024-03-20, Balance as of period end |
| 2021-12-31 | $26.33M | -4.7% | 2023-03-23, Balance as of period end |
| 2020-12-31 | $27.64M | n/a | 2022-03-14, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | 2025-12-31 | $628.44M | n/m |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $350.30M | +69.8% |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $215.60M | -0.1% |
| Cullinan Therapeutics, Inc. (CGEM) | 2025-12-31 | $39.64M | +25.9% |
| Vericel Corp (VCEL) | 2025-12-31 | $133.33M | -5.3% |
| ImmunityBio, Inc. (IBRX) | 2025-12-31 | $1.00B | +15.0% |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | $287.74M | -14.6% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $633.31M | -34.5% |
| Sana Biotechnology, Inc. (SANA) | 2025-12-31 | $256.01M | +2.2% |
Compare VOR, RGNX, GLUE, CGEM side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗